Alnylam
Alnylam and Roche partner for RNAi therapeutic for treatment of hypertension
July 24, 2023Research and Development Alnylam, Cardiology, Roche, hypertension, rnai, zilebesiran
Alnylam Pharmaceuticals has announced that it has entered a strategic agreement with Roche for the development and commercialisation of zilebesiran, …
Alnylam shares positive results from phase 1 trial
July 17, 2023Research and Development ALN-APP, Alnylam, Alzheimer's disease, Cerebral Amyloid Angiopathy, Neurology, clinical trial
Alnylam Pharmaceuticals has announced positive interim results for the ongoing single ascending dose section of its phase 1 study of …
Alnylam’s lumasiran hits main Phase 3 goal in rare renal disease primary hyperoxaluria type 1
June 9, 2020Manufacturing and Production, Research and Development Alnylam, lumasiran, pharma, rare disease
Alnylam has presented promising new Phase 3 data at the European Renal Association-European Dialysis and Transplant Association International Congress for …
NICE recommends Alnylam’s Onpattro for inherited hATTR amyloidosis
July 9, 2019Manufacturing and Production, Sales and Marketing Alnylam, NHS, Onpattro, UK, hATTR amyloidosis, pharma
It’s good news for UK patients as it emerges that the National Institute of Health and Care Excellence has passed …
Alnylam and Sanofi close research phase of 2014’s $700m RNAi rare disease partnership
April 8, 2019Research and Development, Sales and Marketing Alnylam, Genzyme, Sanofi, pharma, rare disease
Alnylam and Sanofi have announced their intention to bring to an end the research and option phase of a $700 …
Regeneron-Alnylam team up to treat NASH
March 22, 2018Research and Development, Sales and Marketing Alnylam, Regeneron, biotech, drugs, nash, pharma, pharmaceutical
Coming on the back of a Regeneron research piece published in the New England Journal of Medicine, the company announced …
Alnylam’s shares plunge by 42% after deaths in clinical trials
October 6, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alnylam, Shares, clinical trials, deaths, failure, market value, phase III, revusiran
Alnylam Pharmaceuticals’ shares lost close to half of their value as it was forced to end a trial of its …
Former Cubist chief executive Michael Bonney to chair board at Alnylam
December 22, 2015Manufacturing and Production, Research and Development, Sales and Marketing Alnylam, David Pyott, michael bonney
Michael Bonney, current board member and former chief executive of Cubist Pharmaceuticals, has been appointed as chairman of Alnylam Pharmaceuticals …
Genzyme opts into Alnylam’s Thrombosis program
October 2, 2015Medical Communications, Research and Development Alnylam, Genzyme, Sanofi, haemophilia
Sanofi subsidiary Genzyme has elected to opt into Alnylam’s investigational ALN-AT3 hemophilia program for development and potential future commercialisation in …
Alnylam poaches VP from Bristol-Myers Squibb
November 4, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alnylam, pushkal garg
US-based RNAi therapeutics firm Alnylam Pharmaceuticals has appointed Dr Pushkal Garg to the position of senior vice president of its …
Sanofi pays $700m to expand rare disease portfolio
January 13, 2014Research and Development, Sales and Marketing Alnylam, Sanofi, rare sidease
Sanofi and Alnylam have announced the expansion of their 2012 agreement to develop and sell treatments for rare genetic diseases. …
Regulus names Stelios Papadopoulos as chairman
June 12, 2013Manufacturing and Production, Research and Development, Sales and Marketing Alnylam, Exelixis, Regulas
Biopharma firm Regulas Therapeutics has named Stelios Papadopoulos chairman of its Board of directors. Papadopoulos assumes the role from John …
Alnylam cuts workforce by a third
January 23, 2012Research and Development, Sales and Marketing Alnylam, Novartis, job cuts, rnai
Alnylam will cut 33% of its workforce this year as it looks to focus on developing its own products. The …
GSK taps Alnylam tech for vaccine production
November 7, 2011Manufacturing and Production, Sales and Marketing Alnylam, GSK, vaccines
GlaxoSmithKline has teamed up with gene silencing specialist Alnylam Pharmaceuticals in a project aimed at speeding up the production of …
Latest content
Five Facts about cardiovascular disease
Artificial hearts: a century of innovation
